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Abstract The discovery that obesity promotes macrophage
accumulation in visceral fat led to the emergence of a new
field of inquiry termed Bimmunometabolism^. This broad
field of study was founded on the premise that inflammation
and the corresponding increase in macrophage number and
activity was a pathologic feature of metabolic diseases.
There is abundant data in both animal and human studies that
supports this assertation. Established adverse effects of in-
flammation in visceral fat include decreased glucose and fatty
acid uptake, inhibition of insulin signaling, and ectopic tri-
glyceride accumulation. Likewise, in the atherosclerotic
plaque, macrophage accumulation and activation results in
plaque expansion and destabilization. Despite these facts,
there is an accumulating body of evidence that macrophages
also have beneficial functions in both atherosclerosis and vis-
ceral obesity. Potentially beneficial functions that are common
to these different contexts include the regulation of
efferocytosis, lipid buffering, and anti-inflammatory effects.
Autophagy, the process by which cytoplasmic contents are
delivered to the lysosome for degradation, is integral to many
of these protective biologic functions. The macrophage uti-
lizes autophagy as a molecular tool to maintain tissue integrity
and homeostasis at baseline (e.g., bone growth) and in the face
of ongoing metabolic insults (e.g., fasting, hypercholesterol-
emia, obesity). Herein, we highlight recent evidence
demonstrating that abrogation of certain macrophage func-
tions, in particular autophagy, exacerbates both atherosclerosis
and obesity-induced insulin resistance. Insulin signaling
through mammalian target of rapamycin (mTOR) is a crucial
regulatory node that links nutrient availability to macrophage
autophagic flux. A more precise understanding of the meta-
bolic substrates and triggers for macrophage autophagy may
allow therapeutic manipulation of this pathway. These obser-
va t ions underscore the complexi ty of the f ie ld
Bimmunometabolism^, validate its importance, and raise
many fascinating and important questions for future study.
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Background
The idea that inflammation, and specifically the macrophage
foam cell, is vital to the initiation and progression of athero-
sclerosis dates back to initial observations by the pathologist
RudolphVirchow and studies in rabbits in 1958 [1]. A seminal
paper by Hotamisligil and colleagues in 1993 demonstrated
increased tumor necrosis factor alpha (TNF-α) messenger
RNA (mRNA) expression in the visceral adipose of obese
mice and neutralization of TNF-α led to improved insulin
stimulated glucose uptake [2]. They postulated that there
may be a link between obesity, insulin resistance (IR), and
inflammation [2]. However, the cellular source of TNF-α
was not clear until 2003, when two simultaneously published
papers demonstrated that obesity results in inflammation and
macrophage accumulation in epididymal adipose tissue [3, 4].
Since that time, there have been hundreds of papers demon-
strating that abrogation of inflammation can improve or pre-
vent atherosclerosis or obesity-associated insulin resistance
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(IR) in mice. Searching PUBMED for the terms Bmyeloid
specific knockout ANDmetabolism^ returns 2259 references,
half of which have been published in the last 5 years. There are
many excellent reviews on the adverse effects of chronic in-
flammation in these diseases and that will not be the focus of
this paper [1, 5, 6]. However, the fact that clinical trials of anti-
inflammatory medications in diabetes have not been over-
whelmingly positive suggests that the pathophysiology is
more complex than it may appear [7].
In normal conditions, both arteries and adipose tissue have
a population of resident macrophages [8]. White adipose tis-
sue (WAT) includes the subcutaneous or inguinal (iWAT) and
visceral adipose tissue (VAT), the latter being more prone to
inflammation. VAT includes the epididymal (eWAT),
parametrial (pWAT), and mesenteric (mWAT) depots, among
others. Macrophages exert multiple and varied effects in these
tissues depending upon the physiologic conditions. Their
number and activity is in constant flux, via recruitment of
monocytes from the blood, proliferation of local tissue mac-
rophages, egress to lymphatics, and cell death. This makes
studies examining an endpoint at a single point in time (e.g.,
atherosclerosis or IR after 12 weeks of high fat diet (HFD))
very difficult to interpret. For example, silencing of TNFα
expression in the eWATmacrophages of ob/ob mice improves
glucose tolerance [9]. Yet, silencing of lipoprotein lipase
(LPL) in eWAT macrophages reduces foam cell formation
and worsens glucose tolerance [10]. Furthermore, although
short-term HFD (less than 1 week) results in obesity and
eWAT inflammation, IR is not improved by depleting macro-
phages or lymphocytes under these conditions [11]. In fact, it
appears that the adipocyte plays a cell-autonomous role in the
development of IR that is dependent primarily upon cell size
but also its metabolic substrates (saturated vs. unsaturated fat-
ty acids) [12]. Hence, the role that macrophages play in IR and
other pathologies is very complex, dependent upon time, con-
text, and other host-specific factors.
Defining macrophages and activation states
Traditionally, macrophage polarization has been dichoto-
mized into classical (M1) or alternative (M2) activation.
These distinctions were developed based upon the in vitro
response of macrophages to INFγ or IL4 and IL13, respec-
tively [13]. We now know that this is an oversimplification,
and that in vivo macrophages are very adaptable and exhibit a
broad range of activation states. Nonetheless, this is a useful
framework that we shall expand upon. M2 activation is a
characteristic feature of tissue resident macrophages; which
account for approximately 10–15 % of stromal cells in lean
eWAT [13]. M2 macrophages remodel extracellular matrix
(ECM), regulate angiogenesis, and have anti-inflammatory
effects, essential functions for normal growth of adipose tissue
(Fig. 1). They secrete anti-inflammatory cytokines such as
IL10 and are dependent upon the transcription factors
STAT6, IRF-4, and PPARγ for their development. In mice,
tissue resident M2 macrophages are generally characterized
by the cell surface markers F480+, CD11b+, and CD11c-
[14]. In obesity, blood monocytes infiltrate eWAT, at least
partially via CCR2 receptors in response CCL2 ligand, and
differentiate into M1 macrophages (F480+, Cd11b+, and
Cd11c+ cells) [14]. Again, it should be emphasized that these
distinctions are very complex, dynamic, and time dependent.
For example, there are at least three populations of recruited
interstitial macrophages after 8 weeks of HFD (Mgl1+/
CD11c-, Mgl1Med/CD11c+, and Mgl1-/CD11c+) [15]. The lat-
ter subset is typically M1 polarized and associated with
Bcrown-like structures^; but many CD11c+cells express both
M1 and M2 type mRNAs, and M2 polarization increases with
longer duration of HFD (12 weeks) [15]. It is still helpful to
think of M1 macrophages as those responding to a Th1 re-
sponse, with anti-microbial activity, and expressing inflamma-
tory cytokines such as TNFα, IL1β, and IL6 (Fig. 1). M1
activation of macrophages is dependent upon the transcription
factors STAT1 and IRF-5. Deletion of CCR2 on circulating
monocytes reduces eWATmacrophage accumulation in obese
mice by 40% [16]. Therefore, although this chemotactic path-
way is important, there must be additional adipose-specific
cues that stimulate inflammation [16]. The fact that many
CD11c+ cells surround dying adipocytes (epididymal and
mesenteric) in Bcrown-like structures^ suggests that the
necro-apoptotic adipocyte may be one such cue [17, 18]. In
addition to infiltration, proliferation of tissue resident macro-
phages also contributes to a local pro-inflammatory subset in
eWAT and atherosclerotic plaques [19, 20]. The net result is a
dramatic increase in the total number of macrophages in obese
as compared to lean eWAT, numbering 45–60% of the stromal
fraction [13]. Chronic inflammation in eWAT results in phys-
iological dysfunction of adipocytes, excess free fatty acid
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Fig. 1 The spectrum of macrophage polarization. Although macrophage
function has typically been dichotomized into classical (M1) or alterna-
tive (M2), recent data highlights the limitations of this classification and
underscores the potential functional utility of Bmetabolically^ (MMe)
activated subsets [13, 14, 30]. Such a subset is characterized by proteins
responsible for lipid uptake (CD36), storage (PLIN2), and export to high-
density lipoproteins (ABCA1)
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release, hepatic and systemic inflammation, and ectopic lipid
deposition (liver, heart, skeletal muscle) [21]. Many studies
have contributed to this notion; for example, ablation of
CD11c+macrophages improves HFD-induced IR [22].
M2 polarization and adaptive thermogenesis
The importance of tissue resident M2macrophages in adipose
tissue biology has been highlighted by a growing body of
literature that demonstrates their role in supporting brown
adipose tissue (BAT) function [23–27]. In contrast to WAT,
which stores triglyceride, BAT oxidizes fatty acids via
uncoupled oxidative phosphorylation to generate heat via
non-shivering thermogenesis. A third type of adipocyte,
termed the Bbeige^ or Bbrite^ adipocyte, is found in WAT
depots, but can be recruited via catecholamines to induce a
thermogenic gene program (e.g. UCP1, PGC1α). The activa-
tion of brown or Bbeige^ adipocytes hold great promise as a
treatment for obesity and there is growing interest in finding
methods to stimulate their growth/function. Interestingly, ex-
posure to the cold results in M2 activation of tissue resident
macrophages in iWAT and BAT [25]. In fact, these resident
cells may be required for expression of a thermogenic gene
program in BAT and lipolysis of triglyceride in iWAT, which
is the fuel for BAT thermogenesis [25]. Whereas it has always
been assumed that sympathetic innervation of fat depots pro-
vided catecholamines to stimulate lipolysis and thermogene-
sis, M2 ATMs induce tyrosine hydrolase (TH) upon cold
exposure and may produce, surprisingly, a significant amount
of adipose tissue catecholamines [25]. Depletion of BAT tis-
sue resident macrophages via clodronate, or abrogation of M2
polarization in IL4 receptor knockout macrophages
(IL4RαLoxP/LoxP LysMCre mice), reduced induction of thermo-
genic genes in BAT and prevented maintenance of core body
temperature upon exposure to 4 °C [25]. More recent work
has unraveled a network of immune cells that may orchestrate
this process [26, 27]. M2 polarization of ATMs is promoted
by paracrine secretion of IL4 by local eosinophils.
Eosinophils, in turn, may be stimulated by endocrine circu-
lating factors released from muscle or fat, during exercise or
cold exposure, respectively [26, 27]. Reducing environmental
temperature from 28 to 4 ° C dramatically alters the BAT
transcriptome [28]. Among the many regulated gene net-
works, upregulation of AMPK and downregulation of
mTOR signaling pathways was noted [28]. Thus, cold stress
is analogous to fasting conditions and could potentially stim-
ulate autophagic pathways in macrophages or other cells (see
below). To summarize, just as prevention of M1 macrophage
polarization or infiltration may be beneficial to adipose tissue
metabolism, stimulation of M2 polarization in ATMs may be
beneficial in iWAT and BAT to promote adaptive thermogen-
esis and energy expenditure.
The role of adipocyte autonomous inflammation
Whereas decreasing monocyte recruitment to VAT is benefi-
cial in mouse models of DIO, Asterholm et al. recently pub-
lished a provocative paper which demonstrates that reducing
inflammatory chemokines elaborated by adipocytes them-
selves during short-term HFD impairs adipose tissue growth
and expansion, and results in a worsening of IR [29]. The
authors used three different mouse models to abrogate inflam-
mation specifically in adipose tissue. First, HFD-fed mice ex-
pressing a dominant negative TNFα (dnTNFα) transgene
driven by the aP2 promoter were leaner but more IR than
control littermates [29]. This was thought to be due to de-
creased adipogenesis in the eWAT and iWAT of dnTNFα
mice. In a second model, the authors expressed a novel
adipose-specific transgene (RID) that broadly inhibits canon-
ical pro-inflammatory pathways. RID mice were also lean and
had smaller iWAT, eWAT, and mWAT depots. Interestingly,
there was greater fibrosis in the RID adipose tissue, suggesting
that a function of acute low-grade inflammation in adipose
tissue is to allow for degradation of extracellular matrix
(ECM) and adipogenesis [29]. Finally, they utilized inducible
expression of IκBα to inhibit NFκB signaling specifically in
adipocytes. In comparison to wild type mice, transgenic mice
had decreased eWATweight, increased liver weight, and were
more glucose intolerant after 8 weeks of HFD [29]. The au-
thors concluded that adipocyte initiated inflammation is nec-
essary for adipogenesis, because macrophages are needed to
remodel ECM and promote angiogenesis, allowing for fat pad
growth [29]. There may be depot-specific differences in the
role of adipocyte inflammation; for example, inflammation in
mWAT stimulates angiogenesis and growth of this depot,
allowing for proper intestinal barrier function in obese condi-
tions [29].
BMetabolic^ activation of macrophages
In addition to this beneficial role of inflammation in adipose
tissue biology, recent evidence suggests that our definition of
Binflammation^ in metabolic contexts may be incomplete
[30]. Using a proteomics approach to study M1 macrophage
cell surface proteins in vitro, Kratz et al. found a panel of three
markers for M1 activation that are common to human and
mouse macrophages; CD274, CD38, and CD319 [30]
(Fig. 1). These three markers were validated on macrophages
from the airway of patients with cystic fibrosis, which are
chronically exposed to bacterial pathogens. However, none
of these markers were increased in the stromal fraction of
VAT from obese humans (omental) or mice (eWAT), despite
increased mRNA levels of TNFα and IL1β from these same
samples [30]. The authors hypothesized that obesity does not
induce M1 macrophage polarity per se, but perhaps a distinct
macrophage phenotype [30]. By exposing macrophages to
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high levels of palmitate, insulin, and glucose, they found a
panel of markers (Abca1, Cd36, Plin2) that were unique for
Bmetabolic activation (MMe)^, and did not overlap with
known M1 or M2 markers. Other groups have also found that
markers of pro-inflammatory macrophages (M1) are not as
abundant in obese VAT as originally thought, especially when
total macrophage number is accounted for [3, 4, 14].
Expression of the consensus MMe markers was validated in
VAT from obese humans and mice, and their induction was
shown to be independent of type 1 interferon or toll-like re-
ceptor signaling [30]. Instead, PPARγ and sequestosome-1
(p62) regulated expression of the MMe markers CD36,
ABCA1, and PLIN2 [30]. p62-/- macrophages, and macro-
phages treated with the PPARγ antagonist T0070907, failed
to induce MMe markers after palmitate treatment and
overproduced TNFα and IL1β. Therefore, there may be a link
between metabolic activation and anti-inflammatory effects.
The role of PPARγwas not surprising, given its known effects
as a regulator of metabolic and anti-inflammatory pathways.
However, the mechanism bywhich p62 suppresses expression
of TNFα and IL1βwas less clear. p62 is normally degraded in
the autophagolysosome and accumulates when autophagy is
blocked [30]. Upregulation of p62 suggested that autophagy
was activated but flux was reduced inMMemacrophages; this
upregulation was correlated with palmitate uptake. Indeed,
increasing palmitate concentrations increased the levels of
p62, in a CD36-independent manner [30]. To summarize,
there appears to be an additional subset of macrophages acti-
vated by metabolic factors (MMe) that is distinct from tradi-
tional M1 or M2 classifications (Fig. 1). The accumulation of
palmitate in macrophage autophagolysosomes may contribute
to the anti-inflammatory properties of this novel subset. The
precise mechanism of palmitate uptake, and the biological
significance of MMe ATMs, has yet to be elucidated.
Macrophage autophagy and lipid metabolism
There are three main types of autophagy [31–33].
Macroautophagy refers to the engulfment of cytosolic con-
tents into double membrane vesicles called autophagosomes.
This process can be selective or non-selective [31]. A second
type of autophagy is microautophagy, which is the direct
phagocytosis of cytosolic material by the lysosomal mem-
brane. Finally, a third form of autophagy is termed
chaperone-mediated autophagy (CMA). Specific motif-
containing proteins are recognized by chaperones such as heat
shock cognate protein of 70 kDa (hsc70) and then delivered to
the surface of the lysosome [31]. CMA has recently been
shown to contribute to lipid droplet metabolism, although
the degradation of lipids by selective macroautophagy, or
Blipophagy ,^ is thought to be most operative in metabolic
disease, and that is the process that we refer to here [34–36].
The findings by Kratz et al. and others suggest that the
macrophage utilizes autophagy to metabolize lipid in condi-
tions of fatty acid excess [14, 30, 37]. How and whymight this
occur?
In fasting conditions, when adipocyte lipolysis is maximal-
ly activated, there is a sudden and abundant increase in eWAT
lipid-laden ATMs [38, 39] (Fig. 2). It is thought that these
macrophages are recruited to buffer the acute local increase
in FFA concentrations because depletion of macrophages after
a 24 h fast results in a dramatic rise in plasma FFA [38].
Whether or not macrophage autophagy is activated in these
circumstances is not known.
On the other hand, autophagy may be stimulated in eWAT
ATMs during obesity. This possibility was recently raised by
Xu et al., who performed microarrays of eWAT in lean and
obese mice and correlated the results with three phenotypes:
body mass, fasting insulin, or macrophage-specific gene ex-
pression [14]. Different transcriptional networks were regulat-
ed for each condition, but only one was upregulated in all
three; lysosomal biogenesis [14]. Proteins, important for au-
tophagy and lysosomal biogenesis, were enriched in macro-
phages from the stromal fraction of eWAT from obese mice. In
comparison to lean mice, ATMs from obese mice doubled
their lysosome content, as measured by Lysotracker accumu-
lation (26 vs. 57%). Although lysosomes accumulated in both
F480+/Cd11b+ and F480+/Cd11b+/Cd11c+ cells, they were
greater in F480+/Cd11b+/Cd11c+ macrophages. Microscopic
analysis of these lipid-laden cells demonstrated two classes of
lipid droplets: larger bodipy positive droplets with and without
surrounding lysosomes and smaller more numerous droplets
that co-localized with lysosomal markers [14]. Exposure of
bone marrow-derived macrophages to eWAT in vitro induced
expression of genes involved in lipid uptake (Msr1, Plin2) and
lysosomal biogenesis (Atp6v0d2, Lipa, Ctsk), but not classic
M1 activation (TNFα, Tlr2, Tlr4) [14]. Inhibition of lysosom-
al function using either chloroquine or Bafilomycin A1 result-
ed in a marked accumulation of macrophage lipid content.
These results were consistent with the subsequent studies by
Kratz et al., suggesting that obesity results in a unique activa-
tion profile of ATMs, characterized by induction of lipid up-
take and lysosomal pathway encoding genes [30].
These data suggest that macrophages in eWAT take up and
store lipid released from dysfunctional adipocytes, leading to
the formation of macrophage Bfoam cells^. Stored lipid is
likely metabolized predominantly by lysosomal degradation;
however, it is possible that stored lipid is also metabolized by
selective macro-autophagy or Blipophagy .^ This process was
originally described by Singh et al. in 2009 [40]. Hepatocytes
deficient in autophagy-related protein 5 (Atg5), when chal-
lenged with oleic acid, have markedly enlarged lipid droplets.
Animals with hepatocyte-specific autophagy-related protein 7
(Atg7) deletion developed marked hepatosteatosis due to
blocked autophagy and resultant reduced lipolysis [40].
Therefore, autophagy appears to serve a protective effect in
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the liver by preventing hepatosteatosis in the setting of HFD.
Furthermore, this protection is at least partially mediated by
lysosomal acid lipase (LAL) and not only neutral cytoplasmic
lipases (HSL, Nceh1, CEH) [41, 42]. Autophagy in
preadipocytes regulates adipogenesis, and its inhibition pre-
vents adipocyte differentiation in vitro and in vivo [43].
Whole body Atg5-/- and Atg7-/- mice die at birth, but
adipocyte-specific ablation of Atg7-/- results is reduced in
leaner, more insulin-sensitive mice, with more brown adipose
tissue [43, 44]. Whether or not macrophage specific loss of
autophagy exacerbates IR in obese mouse models is not yet
known. However, there is abundant recent evidence demon-
strating that macrophage autophagy is protective against ath-
erosclerosis [37, 41, 45].
Macrophage autophagy and atherosclerosis
The idea that macrophage autophagy might be beneficial in
limiting atherosclerosis stemmed from the observation of
autophagosomes in atherosclerotic plaque on electron micros-
copy [46]. Additionally, as defective efferocytosis and the
accumulation of cholesterol crystals are hallmarks of the ath-
erosclerotic plaque, it is intuitive that autophagy may be pro-
tective, by potentially clearing this cellular debris. Finally,
interventions that activate autophagy, such as fasting and
treatment with the mTOR inhibitors everolimus and sirolimus,
reduce atherosclerosis in mice [37].
Razani et al. tested the hypothesis that autophagy defective
mice on the apoliprotein E null (Apoe-/-) background might
develop worse atherosclerosis [37]. Beclin-1/Atg6 heterozy-
gous deficient mice, which are only haploinsufficient for au-
tophagy, did not develop worse atherosclerosis than Apoe-/-
littermates. However, macrophage-specific Atg5 knockout
mice on the Apoe-/- background (Atg5-mϕ Apoe-/-) developed
dramatically worse atherosclerosis. Reduced autophagic flux
was demonstrated by increased p62 protein levels in the aortas
of Atg5-mϕ Apoe-/- mice. In addition to the increased athero-
sclerotic area, Atg5-mϕ Apoe-/- mice hyper-secreted IL1β in
response to LPS and had markedly reduced cholesterol efflux
[37].
It is notable that cholesterol crystals in advanced plaques
not only activate the inflammasome but also block autophagic
processing. This is reminiscent of the effect of palmitate to
inhibit autophagy and subsequently repress the anti-
inflammatory effects of autophagy [30]. Hence it appears that
the metabolic substrates of autophagy, depending upon their
suitability for lysosomal degradation, may determine autoph-
agic flux. Poorly digestible substrates (oxidized LDL,
lipofuscin, ceroid) will result in stalled autophagy and stimu-
lation of pro-inflammatory pathways [30, 37, 47]. For
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Fig. 2 Regulation of lipid metabolism in foam cells and tissue resident
macrophages. (step 1, blue) In basal conditions, macrophages take up
glucose to generate energy via oxidative metabolism, storing excess
glucose in lipid droplets after de novo lipogenesis. (step 2, green) In
fasting conditions, neutral lipases at the lipid droplet surface hydrolyze
stored triglyceride (TG) to fatty acids (FA), which undergo beta-oxidation
in adjacent mitochondria to generate adenosine triphosphate (ATP). (Step
3, red) In obesity or hypercholesterolemia, macrophages in the plaque or
visceral adipose tissue may endocytose lipoproteins/lipid via scavenger
receptors (CD36, SRA) or via micro pinocytosis. Engulfed lipoproteins
are metabolized via lysosomal degradation. (step 4, black) Some stored
lipid may also be metabolized via autophagy, which is initiated by for-
mation of a phagophore. AMP activated protein kinase (AMPK) and
mammalian target of rapamycin (mTORC1), respectively, activate and
inhibit this process. The autophagosome fuses with the lysosome to gen-
erate the autolysosome. (step 5, orange) In the autolysosome lysosomal
acid lipase (LAL) hydrolyzes cholesterol ester (CholE) to cholesterol
(Chol). Whether or FA generated from the hydrolysis of CholE or TG
are available for beta-oxidation is not yet known (not shown). However,
the export of cholesterol is dependent on this process. The export of
cholesterol is facilitated by the proteins of Niemann-Pick disease, type
C1,2 (NPC1/2), and member 1 of human transporter subfamily ABCA
(ABCA1). Depending upon the substrates within the autolysosome au-
tophagy may be blocked at this step. This will result in the accumulation
of sequestosome-1 (p62) and lipid in the autolysosome and prevent cho-
lesterol efflux to high density lipoprotein (HDL). Decreased autophagic
flux will also cause leakage of autolysosome contents into the cytoplasm
(cathespins, reactive oxygen species) and cause activation of the
inflammasome or unfolded protein response. These latter effects contrib-
ute to worsening of local inflammation or programmed cell death
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example, the accumulation of undigested cholesterol crystals
stimulates the inflammasome, whereas palmitate and other
saturated fatty acids activate the unfolded protein response
[34, 48]. In this way, atherosclerosis, obesity, and
hepatosteatosis may all represent acquired lysosomal storage
disorders [49]. Compounds that promote the mobilization of
cholesterol crystals from the lysosome and into the cytoplasm
(e.g.,β-cyclodextrins) have been promoted as potential thera-
peutic compounds for these disorders [50–52]. This is in con-
trast to oleate and other unsaturated fatty acids that stimulate,
but do not stall, flow through the autophagy pathway [34].
Stalled autophagy not only triggers inflammation and lipid
droplet accumulation, but it prevents the hydrolysis of choles-
terol ester and subsequent efflux of cholesterol to apo-A1 [41].
It was previously thought that cytoplasmic neutral cholesterol
esterases (HSL, ATGL) were responsible for hydrolysis and
mobilization of cholesterol from foam cells. However,
Ouitmet et al. showed that in lipid-loaded macrophages, cho-
lesterol efflux to apoA-1 is dependent on lysosomal acid li-
pase (LAL) [41]. An inhibitor of LAL (lalistat) prevented
cholesterol efflux to apo-A1. RCT in vivo was reduced in
mice given lipid-loaded macrophages from Atg5-/- donors.
Therefore, mobilization of cholesterol for RCT from foam
cells is dependent upon autophagy. Foam cells accumulate
lipid droplets in an unregulated fashion via non-selective up-
take of triglyceride rich lipoprotein particles (TRLP) by scav-
enger receptors (SR-A1, SR-B1, CD36), whereas non-lipid
laden macrophages take up TRLP in a regulated fashion, via
lipoprotein receptors (LDLR). How do lipid-laden macro-
phages sense the metabolic milieu and regulate autophagic
pathways?
MTOR links environmental cues to autophagy
and nutritional status
Mammalian target of rapamycin (mTOR1) provides a link
between the presence of extracellular nutrients/growth factors
and the stimulation of cell growth and protein synthesis [53].
Stimulation of the insulin receptor leads to activation of
phosphatidylinositiol-3 kinase (PI3K), phosphorylation of
Akt, and downstream activation of mTOR1. It is important
to note that the effect of PI3K on autophagy is class depen-
dent; class 1 PI3 kinases inhibit autophagy (by activating
mTOR1), whereas class 3 PI3 kinases activate autophagy by
inducing beclin 1 [54]. Activation of mTOR1 inhibits autoph-
agy by several mechanisms. mTOR1 phosphorylates ATG13
and ULK1/2, which are components of the autophagy initiat-
ing UNC-5 like autophagy activating (ULK) complex [55].
mTOR1 also phosphorylates ATG14L, causing inhibition of
the associated class 3 PI3 kinase VPS34. Finally, mTOR1
phosphorylates autophagy/beclin 1 regulator 1 (AMBRA1)
[46, 55, 56]. In this way, mTOR activation signals cells that
environmental conditions favor cellular growth, and
autophagy or Bself-digestion^ is not necessary for the provi-
sion ofmetabolites for cellular growth and ATP synthesis [46].
In contrast, under fasting conditions, when there are lower
amounts of extracellular nutrients and growth factors,
mTOR1 is not activated, and Atg1 kinase activity is
derepressed, therefore stimulating autophagy for the provision
of cellular nutrients. The importance of this pathway to cellu-
lar metabolism is reflected in its inter-species conservation,
most dramatically seen in C.elegans, where fasting and stim-
ulation of autophagy promote longevity and delay cellular
senescence [57]. These insights have led to the understanding
that reduced insulin signaling promotes longevity and might
have other beneficial effects.
Interestingly, deletion of the insulin receptor specifically
from macrophages, as opposed to whole body deletion, im-
proves atherosclerosis on the Apoe-/- background [58]. In con-
trast, hepatic insulin receptor deletion promotes atherosclero-
sis even in wild type mice, due to the development of
Bselective^ insulin resistance [59]. Hepatic insulin receptor
knockout stimulates VLDL synthesis resulting in high blood
triglyceride-rich lipoprotein levels and atherosclerosis. dele-
tion of the insulin receptor in macrophages results in de-
creased atherosclerosis and inflammatory cytokine production
bymacrophages, despite identical blood lipoprotein levels and
metabolic features [58].
Myeloid-specific insulin receptor knockout also provides pro-
tection against DIO [60]. The mechanism was thought to be due
to increasedmacrophage apoptosis in the absence of insulin and/
or decreasedmacrophage infiltration into adipose tissue [60].We
speculate that an additional protective effect of myeloid specific
insulin receptor knockout may be due to reduced mTOR1 acti-
vation and resultant stimulation of autophagy. Numerous other
studies in mice and rabbits have demonstrated that inhibition of
mTOR1 signaling by pharmacologic (rapamycin analogs) or
genetic approaches (mTOR1 siRNA) leads to stimulation of
autophagy, a reduction in atherosclerotic lesion size, and stabili-
zation of the fibrous plaque [46, 54].
The protective functions of macrophage autophagy extend
beyond Blipophagy^ in the atherosclerotic plaque or VAT.
Autophagy also helps to prevent apoptosis, promote
efferocytosis of necrotic cells, and digest cellular components
(e.g., mitochondria) damaged by oxidative stress [61]. For
example, 7-ketocholesterol has been shown to induce autoph-
agy and prevent induction of smooth muscle cell apoptosis by
fluvastatin, through yet to be identified mechanisms [62]. The
cardioprotective effects of adiponectin (Acrp30) may be par-
tially due to the stimulation of autophagy in foam cells of the
atherosclerotic plaque [63]. Transplant of Acrp30-deficient
perivascular fat to the carotid artery of Apoe-/- mice results in
worse atherosclerosis and decreased macrophage autophagy;
Acrp30 also stimulates autophagy in macrophages in vitro
[63]. This effect of Acrp30 may be mediated by AMP-
activated protein kinase (AMPK), a known antagonist of
272 J Mol Med (2016) 94:267–275
mTOR1 signaling whose activity is increased by fasting [53].
AMPK mediates these effects by activating tuberous sclerosis
complex 2 (TSC2) and also by direct serine phosphorylation
of raptor [53].
Conclusions
For over a decade, there has been fervent research aimed at
deciphering the effects of inflammation on the pathophysiol-
ogy of atherosclerosis and obesity-associated IR. The lipid-
laden macrophage is the central orchestrator of the innate im-
mune response to modified lipoproteins in the atherosclerotic
plaque and FFAs in obese VAT depots. There is little doubt
that chronic inflammation incited by the lipid-laden macro-
phage contributes significantly to the pathophysiology of
these disorders [22, 64, 65]. However, there is increasing ev-
idence that macrophages also play beneficial roles in the pre-
vention of atherosclerosis and obesity-induced IR. These ben-
eficial effects relate to the maintenance of tissue homeostasis,
many of which are mediated by macrophage autophagy.
Examples of such effects include the buffering and metabo-
lism of excess local lipids, efferocytosis of necrotic cells and
debris, and the prevention of apoptosis. Macrophages in both
atherosclerosis and diet-induced obesity have features of ac-
quired lysosomal storage disorders (e.g., p62 accumulation),
that may be precipitated by specific metabolic substrates (e.g.,
oxLDL, palmitate). Furthermore, the beneficial effects of
macrophage autophagy are highlighted by worsening of ath-
erosclerosis in macrophage-specific knockouts deficient in
this pathway. Such models have yet to be described in obesity.
Nonetheless, we believe that there is sufficient data to warrant
investigation of pharmacologic (mTOR1 inhibitors, AMPK
activators, cyclodextrins) or dietary interventions (fasting) that
may stimulate macrophage autophagy and possibly represent
a novel pathway to prevent or treat cardiometabolic disorders.
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